Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Po

- Single dose of plerixafor on day 4 of PBSC harvest improves CD34+ HSC yield in the graft for poorly mobilizing haploidentical donors.
- Addition of plerixafor results in higher CD4+ T cells in the graft with similar yield of CD8+ T cells without any differential impact on mobilization of Tregs.
- NK cell mobilization is skewed toward CD56+/CD16− subset in both groups.
- Single-dose plerixafor is associated with self-limited mild gastrointestinal side effects in healthy donors with no serious adverse events.
- Plerixafor mobilized PBSC grafts do not affect short- or intermediate-term transplant outcomes for PTCy-based haploidentical HSCT in patients with malignant and nonmalignant diseases.